clinical trial · NCT04817761
SPARK-ALL: Calaspargase Pegol in Adults With ALL
Institut de Recherches Internationales Servier·phase3·terminated·n = 42
Acute Lymphoblastic LeukemiaCalaspargase pegol (S95015)
brief summary
The purpose of this phase 2/3 study is to confirm the recommended doses and to evaluate the safety and pharmacodynamics of Calaspargase pegol for the treatment of adult patients with Philadelphia-negative Acute Lymphoblastic Leukemia.
started
Jul 7, 2021
primary completion
Mar 21, 2025
completion
Mar 21, 2025
last updated
Feb 18, 2026
detailed description
The study will be conducted in 2 parts. Part 1 is a dose confirmation run-in period. Part 2 will enroll the remaining participants at the dose as confirmed or recommended in Part 1.
official title
SPARK-ALL: A Multi-center, Open-label, Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 To >65 Years With Newly-diagnosed Philadelphia-negative ALL.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol